Alistair M. Cook

Alistair M. Cook

Auto-generated profile, based on publicly available information

Alistair M. Cook

National Centre for Asbestos Related Diseases, The University of Western Australia, Perth, Australia

Research Focus & Metrics

Academic Career Length

14Years (2013-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2020 in The Lancet Oncology
Verified
Journal Article
Closed access
ANAnna K Nowak
Anna K Nowak
WLW Joost Lesterhuis
W Joost Lesterhuis
PKPeey-Sei Kok
Peey-Sei Kok
CBChris Brown
Chris Brown
BHBrett Gm Hughes
Brett Gm Hughes
MSMartin R Stockler
Martin R Stockler

1 March 2016 in Cell Reports
Verified
Journal Article
Open access
SUSvetlana Ulyanchenko
Svetlana Ulyanchenko
KOKathy E. O’nEill
Kathy E. O’nEill
TMTanya Medley
Tanya Medley
AFAlison M. Farley
Alison M. Farley
HVHarsh J. Vaidya
Harsh J. Vaidya
CBC. Clare Blackburn
C. Clare Blackburn
Thymic epithelial cells (TECs) are critically required for T cell development, but the cellular mechanisms that maintain adult TECs are poorly understood. Here, we show that a previously unidentified subpopulation, EpCam(+)UEA1(-)Ly-51(+)PLET1(+)MHC class II(hi), which comprises <0.5% of adult TECs, contains bipotent TEC progenitors that can efficiently generate both cortical (c) TECs and medullary (m) TECs. No other adult TEC population tested in this study contains this activity. We demonstrate persistence of PLET1(+)Ly-51(+) TEC-derived cells for 9 months in vivo, suggesting the presence of thymic epithelial stem cells. Additionally, we identify cTEC-restricted short-term progenitor activity but fail to detect high efficiency mTEC-restricted progenitors in the adult thymus. Our data provide a phenotypically defined adult thymic epithelial progenitor/stem cell that is able to generate both cTECs and mTECs, opening avenues for improving thymus function in patients.

1 April 2016 in Current Opinion in Immunology
Verified
Journal Article
Closed access
ACAlistair M Cook
Alistair M Cook
WLW Joost Lesterhuis
W Joost Lesterhuis
ANAnna K Nowak
Anna K Nowak
RLRichard A Lake
Richard A Lake

18 September 2015 in Annals of Oncology
Verified
Journal Article
Open access
PDF file
ANA K Nowak
A K Nowak
ACA M Cook
A M Cook
AMAlison McDonnell
Alison McDonnell
MMM J Millward
M J Millward
JCJ Creaney
J Creaney
RLR A Lake
R A Lake
Data from murine models suggest that CD40 activation may synergize with cytotoxic chemotherapy. We aimed to determine the maximum tolerated dose (MTD) and toxicity profile and to explore immunological biomarkers of the CD40-activating antibody CP-870,893 with cisplatin and pemetrexed in patients with malignant pleural mesothelioma (MPM). Eligible patients had confirmed MPM, ECOG performance status 0–1, and measurable disease. Patients received cisplatin 75 mg/m2 and pemetrexed 500 mg/m2 on day 1 and CP-870,893 on day 8 of a 21-day cycle for maximum 6 cycles with up to 6 subsequent cycles single-agent CP-870,893. Immune cell subset changes were examined weekly by flow cytometry. Fifteen patients were treated at three dose levels. The MTD of CP-870,893 was 0.15 mg/kg, and was exceeded at 0.2 mg/kg with one grade 4 splenic infarction and one grade 3 confusion and hyponatraemia. Cytokine release syndrome (CRS) occurred in most patients (80%) following CP-870,893. Haematological toxicities were consistent with cisplatin and pemetrexed chemotherapy. Six partial responses (40%) and 9 stable disease (53%) as best response were observed. The median overall survival was 16.5 months; the median progression-free survival was 6.3 months. Three patients survived beyond 30 months. CD19+ B cells decreased over 6 cycles of chemoimmunotherapy (P < 0.001) with a concomitant increase in the proportion of CD27+ memory B cells (P < 0.001) and activated CD86+CD27+ memory B cells (P < 0.001), as an immunopharmacodynamic marker of CD40 activation. CP-870,893 with cisplatin and pemetrexed is safe and tolerable at 0.15 mg/kg, although most patients experience CRS. While objective response rates are similar to chemotherapy alone, three patients achieved long-term survival. ACTRN12609000294257.

31 August 2015 in OncoImmunology
Verified
Journal Article
Open access
ACAlistair M. Cook
Alistair M. Cook
AMAlison McDonnell
Alison McDonnell
RLRichard A. Lake
Richard A. Lake
ANAnna K. Nowak
Anna K. Nowak
The glucocorticoid (GC) steroid dexamethasone (Dex) is used as a supportive care co-medication for cancer patients undergoing standard care pemetrexed/platinum doublet chemotherapy. As trials for new cancer immunotherapy treatments increase in prevalence, it is important to track the immunological changes induced by co-medications commonly used in the clinic, but not specifically included in trial design or in pre-clinical models. Here, we document a number of Dex -induced immunological effects, including a large-scale lymphodepletive effect particularly affecting CD4+ T cells but also CD8+ T cells. The proportion of regulatory T cells within the CD4+ compartment did not change after Dex was administered, however a significant increase in proliferation and activation of regulatory T cells was observed. We also noted Dex -induced proportional changes in dendritic cell (DC) subtypes. We discuss these immunological effects in the context of chemoimmunotherapy strategies, and suggest a number of considerations to be taken into account when designing future studies where Dex and other GCs may be in use.

1 January 2020 in Clinical & Translational Immunology
Verified
Journal Article
Open access
PDF file
SKSynat Keam
Synat Keam
SGSuki Gill
Suki Gill
MEMartin Andrew Ebert
Martin Andrew Ebert
ANAnna K Nowak
Anna K Nowak
ACAlistair M Cook
Alistair M Cook
Recent clinical breakthroughs in cancer immunotherapy, especially with immune checkpoint blockade, offer great hope for cancer sufferers – and have greatly changed the landscape of cancer treatment. However, whilst many patients achieve clinical responses, others experience minimal benefit or do not respond to immune checkpoint blockade at all. Researchers are therefore exploring multimodal approaches by combining immune checkpoint blockade with conventional cancer therapies to enhance the efficacy of treatment. A growing body of evidence from both preclinical studies and clinical observations indicates that radiotherapy could be a powerful driver to augment the efficacy of immune checkpoint blockade, because of its ability to activate the antitumor immune response and potentially overcome resistance. In this review, we describe how radiotherapy induces DNA damage and apoptosis, generates immunogenic cell death and alters the characteristics of key immune cells in the tumor microenvironment. We also discuss recent preclinical work and clinical trials combining radiotherapy and immune checkpoint blockade in thoracic and other cancers. Finally, we discuss the scheduling of immune checkpoint blockade and radiotherapy, biomarkers predicting responses to combination therapy, and how these novel data may be translated into the clinic.